Везде

RAS PhysiologyРоссийский физиологический журнал им. И.М. Сеченова Russian Journal of Physiology

  • ISSN (Print) 0869-8139
  • ISSN (Online) 2658-655X

Suppression of Aseptic Inflammation Reduces the Severity of Remodeling of the Pulmonary Artery Branches and Improves Progressing of Experimental Chronic Thromboembolic Pulmonary Hypertension

You can
PII
10.31857/S0869813924050109-1
DOI
10.31857/S0869813924050109
Publication type
Article
Status
Published
Authors
D. D. Vaulina
  • Affiliation: Almazov National Medical Research Centre
Volume/ Edition
Volume 110 / Issue number 5
Pages
799-813
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism, characterized by increased pressure in the pulmonary artery and impaired lysis of thromboemboli. Previously, the presence of aseptic inflammation in CTEPH was identified in the wall of the pulmonary artery branches and perivascularly. However, the role of this inflammation in the CTEPH formation is unknown. The aim of the work was to study the effect of aseptic inflammation on the CTEPH formation and progression. The experiments were performed on 54 male rats. The CTEPH model was reproduced by repeated intravenous administration of partially biodegradable microspheres (MS). Immediately after the last administration of MS, all animals were divided into groups: control CTEPH (c.CTEPH) – saline solution was administered intramuscularly (i/m) for 6 weeks; low dose of prednisolone (LD) – prednisolone was administered i/m at a dose of 1.5 mg/kg; high dose (HD) – prednisolone was administered i/m at a dose of 6 mg/kg; healthy animals. After 6 weeks, the following was performed: treadmill test, TTE, cardiac catheterization with manometry, and histological examination of the lungs. In a separate series of experiments, the severity of inflammatory infiltration of the vascular wall and perivascular zone was assessed by immunohistochemical studies (IHC). In the LD group, there was the decreasing of hypertrophy index (HI) and the percentage of collagen fibers in the vascular wall compared to c.CTEPH. There was a significantly greater reduction in HI compared to HD. In the HD group, there was positive effect on the percentage of collagen fibers in the vascular wall, this parameter did not significantly differ from healthy animals. According to IHC data, prednisolone in low dose effectively suppressed inflammatory infiltration of the vascular wall and perivascular space. The results of the study revealed the ability of prednisolone, by suppressing aseptic inflammation, to reduce the severity of remodeling of the pulmonary artery branches.
Keywords
хроническая тромбоэмболическая легочная гипертензия воспаление фиброз ремоделирование легочной артерии преднизолон крысы
Date of publication
15.05.2024
Year of publication
2024
Number of purchasers
0
Views
44

References

  1. 1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53(1): 1801913. https://doi.org/10.1183/13993003.01913–2018
  2. 2. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group (2022) 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43(38): 3618–3731. https://doi.org/10.1093/eurheartj/ehac237
  3. 3. Yang J, Madani MM, Mahmud E, Kim NH (2023) Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension. Chest 164(2): 490–502. https://doi.org/10.1016/j.chest.2023.03.029
  4. 4. Rådegran G, Kjellström B, Ekmehag B, Larsen F, Rundqvist B, Blomquist SB, Gustafsson C, Hesselstrand R, Karlsson M, Kornhall B, Nisell M, Persson L, Ryftenius H, Selin M, Ullman B, Wall K, Wikström G, Willehadson M, Jansson K, Söderberg S, on behalf of SveFPH and SPAHR (2016) Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014. Scand Cardiovasc J 50(4): 243–250. https://doi.org/10.1080/14017431.2016.1185532
  5. 5. Quadery SR, Swift AJ, Billings CG, Thompson AAR, Elliot CA, Hurdman J, Charalampopoulos A, Sabroe I, Armstrong IJ, Hamilton N, Sephton P, Garrad S, Pepke-Zaba J, Jenkins DP, Screaton N, Rothman AM, Lawrie A, Cleveland T, Thomas S, Rajaram S, Hill C, Davies C, Johns CS, Wild JM, Condliffe R, Kiely DG (2018) The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J 52(3): 1800589. https://doi.org/10.1183/13993003.00589–2018
  6. 6. Lang IM, Dorfmüller P, Vonk Noordegraaf A (2016) The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. Ann Am Thorac Soc 13 Suppl 3: S215–S221. https://doi.org/10.1513/AnnalsATS.201509–620AS
  7. 7. Delcroix M, Vonk Noordegraaf A, Fadel E, Lang I, Simonneau G, Naeije R (2013) Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. Eur Respir J 41(1): 224–232. https://doi.org/10.1183/09031936.00047712
  8. 8. Andersen S, Reese-Petersen AL, Braams N, Andersen MJ, Mellemkjær S, Andersen A, Bogaard HJ, Genovese F, Nielsen-Kudsk JE (2023) Biomarkers of collagen turnover and wound healing in chronic thromboembolic pulmonary hypertension patients before and after pulmonary endarterectomy. Int J Cardiol 384: 82–88. https://doi.org/10.1016/j.ijcard.2023.05.016
  9. 9. Matthews DT, Hemnes AR (2016) Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ 6(2): 145–154. https://doi.org/10.1086/686011
  10. 10. Quarck R, Wynants M, Verbeken E, Meyns B, Delcroix M (2015) Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J 46(2): 431–443. https://doi.org/10.1183/09031936.00009914
  11. 11. Zhang M, Zhang Y, Pang W, Zhai Z, Wang C (2019) Circulating biomarkers in chronic thromboembolic pulmonary hypertension. Pulm Circ 9(2): 2045894019844480. https://doi.org/10.1177/2045894019844480
  12. 12. Koudstaal T, van Uden D, van Hulst JAC, Heukels P, Bergen IM, Geenen LW, Baggen VJM, van den Bosch AE, van den Toorn LM, Chandoesing PP, Kool M, Boersma E, Hendriks RW, Boomars KA (2021) Plasma markers in pulmonary hypertension subgroups correlate with patient survival. Respir Res 22(1): 137. https://doi.org/10.1186/s12931–021–01716-w
  13. 13. Magoń W, Stępniewski J, Waligóra M, Jonas K, Przybylski R, Podolec P, Kopeć G (2022) Changes in Inflammatory Markers in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. Cells 11(9): 1491. https://doi.org/10.3390/cells11091491
  14. 14. Zabini D, Heinemann A, Foris V, Nagaraj C, Nierlich P, Bálint Z, Kwapiszewska G, Lang IM, Klepetko W, Olschewski H, Olschewski A (2014) Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J 44(4): 951–962. https://doi.org/10.1183/09031936.00145013
  15. 15. Reesink HJ, Meijer RC, Lutter R, Boomsma F, Jansen HM, Kloek JJ, Bresser P (2006) Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J 70(8): 1058–1063. https://doi.org/10.1253/circj.70.1058
  16. 16. Smolders VFED, Lodder K, Rodríguez C, Tura-Ceide O, Barberà JA, Jukema JW, Quax PHA, Goumans MJ, Kurakula K (2021) The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression. Cells 10(4): 737. https://doi.org/10.3390/cells10040737
  17. 17. Ferré A, Thille AW, Mekontso-Dessap A, Similowski T, Legriel S, Aegerter P, Demoule A; Réseau Européen de Recherche en Ventilation Artificielle (REVA) research network (2023) Impact of corticosteroids on the duration of ventilatory support during severe acute exacerbations of chronic obstructive pulmonary disease in patients in the intensive care unit: a study protocol for a multicentre, randomized, placebo-controlled, double-blind trial. Trials 24(1): 231. https://doi.org/10.1186/s13063–023–07229–9
  18. 18. Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7(2): 27–31. https://doi.org/10.4103/0976–0105.177703
  19. 19. Karpov AA, Anikin NA, Mihailova AM, Smirnov SS, Vaulina DD, Shilenko LA, Ivkin DY, Bagrov AY, Moiseeva OM, Galagudza MM (2021) Model of Chronic Thromboembolic Pulmonary Hypertension in Rats Caused by Repeated Intravenous Administration of Partially Biodegradable Sodium Alginate Microspheres. Int J Mol Sci 22(3): 1149. https://doi.org/10.3390/ijms22031149
  20. 20. Mukhopadhyay S, Johnson TA, Duru N, Buzza MS, Pawar NR, Sarkar R, Antalis TM (2019) Fibrinolysis and Inflammation in Venous Thrombus Resolution. Front Immunol 10: 1348. https://doi.org/10.3389/fimmu.2019.01348
  21. 21. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB; PULSAR Trial Investigators (2021) Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 384(13): 1204–1215. https://doi.org/10.1056/NEJMoa2024277
  22. 22. Barnes PJ, Adcock IM, Ito K (2005) Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 25(3): 552–563. https://doi.org/10.1183/09031936.05.00117504
  23. 23. Chapados I, Lee TF, Chik CL, Cheung PY (2011) Hydrocortisone administration increases pulmonary artery pressure in asphyxiated newborn piglets reoxygenated with 100% oxygen. Eur J Pharmacol 652(1–3): 111–116. https://doi.org/10.1016/j.ejphar.2010.10.089
  24. 24. Gluskowski J, Hawrylkiewicz I, Zych D, Zieliński J (1990) Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 3(4): 403–407.
  25. 25. Kerr KM, Auger WR, Marsh JJ, Devendra G, Spragg RG, Kim NH, Channick RN, Jamieson SW, Madani MM, Manecke GR, Roth DM, Shragg GP, Fedullo PF (2012) Efficacy of methylprednisolone in preventing lung injury following pulmonary thromboendarterectomy. Chest 141(1): 27–35. https://doi.org/10.1378/chest.10–2639
QR
Translate

Индексирование

Scopus

Scopus

Scopus

Crossref

Scopus

Higher Attestation Commission

At the Ministry of Education and Science of the Russian Federation

Scopus

Scientific Electronic Library